David Wichmann is stepping down as chief executive of UnitedHealth Group after less than four years running Minnesota's largest company, an abrupt move that surprised investors Thursday and apparently drove a one-day decline in the Minnetonka-based company's stock price.
Analysts said they don't anticipate a strategy shift as the CEO job passes to Andrew Witty, a onetime chief executive at the pharmaceutical giant GlaxoSmithKline. He currently runs UnitedHealth Group's fast-growing Optum division for health care services.
The timing of Thursday's announcement puzzled some analysts, and investors sent UnitedHealth shares down 2.5%.
Witty only recently returned to the company after a seven-month leave to help the World Health Organization's program to develop and distribute coronavirus vaccines. When Wichmann became CEO in September 2017, the company said the leadership transition had been in the works for almost four years — a period of time that's longer than Wichmann's tenure as chief executive turned out to be, noted David Windley, an analyst with Jefferies.
"I thought it was surprising," Windley said in an interview. "I don't think it's performance driven. I don't think it's inability to execute on strategy or lack of delivery of growth — I don't think those could be the reason."
The value of UnitedHealth Group shares increased 69% during Wichmann's time as chief executive, the company said, while total shareholder return, which factors dividends, has been closer to 79%.
"Absent an explanation or an identifiable 'catalyst' investors are likely to respond negatively if just on uncertainty alone because this was not expected," Matthew Borsch, an analyst with BMO Capital Markets, wrote in a research note early in the day.
From 2008 to 2017, Witty was chief executive and a director of GlaxoSmithKline. At UnitedHealth Group, he becomes chief executive immediately and rejoins the company's board of directors.